How to appeal an Aetna pulmonary hypertension denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal an Aetna pulmonary hypertension denial, file an internal appeal within 180 days of the date on the denial letter through Aetna's member or provider portal, under ACA §2719 + ERISA §503. Aetna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.
What Aetna's policy requires for pulmonary hypertension
Cited policy: Aetna CPB on Endothelin Receptor Antagonists for PAH (CPB #0743)
WHO Group 1 PAH RHC-confirmed. Step-therapy: trial of bosentan or ambrisentan (or generic) before macitentan unless contraindicated. WHO FC II–IV. PH specialist Rx. LFT monitoring per REMS. Concomitant PDE5i / prostacyclin permitted.
How Aetna denies pulmonary hypertension — and how to counter it
Where Aetna pushes back: 1) Must fail bosentan or generic ambrisentan first; 2) Insufficient PDE5i trial; 3) Generic preference (ambrisentan is now generic).
Counter-arguments that hold up: ESC/ERS 2022 treats ERAs as a class with evidence-based selection — macitentan is the ONLY ERA with event-driven morbidity-mortality data (SERAPHIN Pulido NEJM 2013;369(9):809-818, 45% reduction composite endpoint). AMBITION supports upfront macitentan + tadalafil. SERAPHIN-AS open-label extension shows durable benefit. Bosentan carries higher hepatotoxicity (AST/ALT monitoring monthly). For event reduction in a chronic progressive disease, macitentan is medically necessary.
What Aetna typically denies for pulmonary hypertension
Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For pulmonary hypertension, expect:
- UM-2575 medical necessity denials
- Prior auth absent
- Step therapy on specialty drugs
- Out-of-network ER reduction
Treatments most often denied in this category
These are the pulmonary hypertension treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Winrevair (sotatercept)
- Opsumit (macitentan)
- Letairis (ambrisentan)
- Tracleer (bosentan)
- Adcirca/Alyq (tadalafil)
- Revatio (sildenafil)
How to submit the appeal to Aetna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
- File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal an Aetna pulmonary hypertension denial?
Aetna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit an Aetna appeal?
Members can submit through the Aetna member portal at https://www.aetna.com. Providers should use the provider portal at https://www.aetnaprovider.com. Faxed and mailed appeals are accepted but take longer.
What denials does Aetna most often issue for pulmonary hypertension?
For pulmonary hypertension, Aetna most often denies on: 1) Must fail bosentan or generic ambrisentan first; 2) Insufficient PDE5i trial; 3) Generic preference (ambrisentan is now generic). The strongest counters: ESC/ERS 2022 treats ERAs as a class with evidence-based selection — macitentan is the ONLY ERA with event-driven morbidity-mortality data (SERAPHIN Pulido NEJM 2013;369(9):809-818, 45% reduction composite endpoint). AMBITION supports upfront macitentan + tadalafil. SERAPHIN-AS open-label extension shows durable benefit. Bosentan carries higher hepatotoxicity (AST/ALT monitoring monthly). For event reduction in a chronic progressive disease, macitentan is medically necessary.
What if Aetna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Pulmonary hypertension appeal
Upload your Aetna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com